

# Abiomed Committed to Investing in Clinical Research



## Impella Quality (IQ) Database:

### Ongoing Observational, Quality Assurance Data

Quality assurance data collected on nearly 100% of patients who receive an Impella® in the U.S.

Real-world data from more than 90,000 Impella cases in more than 1,300 U.S. centers



## Clinical Research



Abiomed has invested more than \$100 million in clinical research



## cVAD Study:

### Institutional Review Board (IRB) Approved

- Multicenter, independent, real-world clinical study that includes more than 5,000 patients supported with Impella

*Retrospective (2009-2015) and prospective (2016-ongoing)*

- IRB approved including complete data monitoring and Clinical Events Committee adjudication



- Validated by the FDA
- Used to assess best practices



## Ten Randomized Controlled Trials

- Seven attempted RCTs for the emergent patient population have either failed to enroll or randomize
- Two Completed RCTs  
PROTECT II and add STEMI DTU Safety and Feasibility RCT

### Ongoing

- DAN-GER Shock RCT in the cardiogenic shock patient population\*

\* Sponsored by Abiomed

## Improving Patient Outcomes by Leading in



- Real-time, post-market monitoring for patient management

- Global 24x7 clinical support through Abiomed's Clinical Support Center



To learn more about the Impella platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit:  
[www.abiomed.com/important-safety-information](http://www.abiomed.com/important-safety-information)

